| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | ziftomenib (KOMZIFTI) + 7+3 (intensive chemotherapy) newly diagnosed NPM1-m AML, KMT2A-r AML BreakthroughFast TrackOrphan | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 1/2 data readout example | ziftomenib (KOMZIFTI) + 7+3 (intensive chemotherapy) newly diagnosed NPM1-m AML, KMT2A-r AML BreakthroughFast TrackOrphan | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology | |
Phase 1/2 data readout example | ziftomenib (KOMZIFTI) + 7+3 (intensive chemotherapy) newly diagnosed NPM1-m AML, KMT2A-r AML BreakthroughFast TrackOrphan | Phase 1/2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Kura Oncology, Inc.$11.45
-0.63 (-5.22%)
C 50Pipeline Score Overvalued Biotech · Commercial
Market Cap
998.71 M
EPS
-3.35
P/E Ratio
-
Value Trade
13.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
18.27 M
R&D Expenses
65.26 M
Operating CF
-85.85 M
Total Assets
652.55 M
Total Liabilities
544.67 M
Equity
107.88 M
D/E Ratio
12,345
16.46 %
Week
17.68 %
1 Month
32.82 %
3 Month
3.5 %
6 Month
-52.77 %
5 Year
-13.46 %
All Time
Cash Data
Cash Position
580.82 M
Monthly Burn
28.62 M
Runway
18.3 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
1.34 M
52 Week Range
5.45 - 12.49
% held by Insiders
3.13 %
% held by Institutions
95.04 %
Enterprise Value
442.16 M
Total Shares
88.80 M
Short %
19.33 %
Float Shares
78.06 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kura Oncology, Inc.
760Total events
7Upcoming
107Tier-1 (high impact)
2015 – 2028Coverage
Upcoming catalysts 7
Event history 753
Q3 2026
◆Oral PresentationZiftomenibApprovedPresentation
Preliminary KOMET-008 data for ziftomenib and gilteritinib combination
R/R NPM1-m/FLT3-m AMLsource ↗
Q3 2026
◆Oral PresentationDarlifarnibPresentation
Updated Phase 1a data with ~1 year additional follow-up for darlifarnib plus cabozantinib
advanced RCCsource ↗
Jun 14, 2026
◆Oral PresentationZiftomenibApprovedPresentation
Oral presentation of updated frontline ziftomenib/7+3 combination data at EHA 2026
newly diagnosed NPM1-mutant or KMT2A-rearranged acute myeloid leukemiasource ↗
Jun 12, 2026
◆Poster PresentationZiftomenibApprovedPresentation
Poster presentation of exposure-response analysis of ziftomenib combinations at EHA 2026
newly diagnosed and relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemiasource ↗
Jun 11, 2026
▲Oral PresentationZiftomenibApprovedPresentation
Long-term results from KOMET-007 presented at EHA 2026 Congress
newly diagnosed NPM1-mutant or KMT2A-rearranged AMLsource ↗
Jun 11, 2026
▲Full ResultsZiftomenibApprovedClinical Data
Encouraging long-term results from KOMET-007: 12-month OS rate 94% in NPM1-m, 71% in KMT2A-r; CRc 96% and 90% respectively
newly diagnosed NPM1-mutant or KMT2A-rearranged AMLsource ↗
Jun 3, 2026
●Oral PresentationPresentation
Kura to host virtual investor event on darlifarnib data, platform strategy, and development plans
Jun 3, 2026
▲Topline ReadoutDarlifarnibClinical Data
Preliminary Phase 1a data from darlifarnib + adagrasib presented at ASCO 2026
KRAS G12C-mutated cancers (PDAC, NSCLC, CRC)source ↗
Jun 3, 2026
▲Preclinical PoCDarlifarnibPreclinical
Preclinical data demonstrate darlifarnib inhibits RHEB farnesylation and sustains mTORC1 suppression, enhancing anti-tumor activity across RAS inhibitor classes
KRAS-mutant cancerssource ↗
Drug Pipeline Intelligence
C50
Pipeline Score $376M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.4x
rNPV / MCap Top 75%
Micro Cap (rank 229 of 912)
Percentile RankKura Oncology, Inc. carries a moderate pipeline score (50/100), with $1.3B risk-adjusted pipeline value, led by Ziftomenib in Relapsed/Refractory KMT2A-r Acute Leukemia (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ziftomenib Small molecule | Acute Myeloid Leukemia (AML) | Phase 3 | NCT07007312 | 87% | $777M | RECRUITING | 1,300 | VERY_FAST | B (77) | Nov 1, 2031 | MODERATE_RISK | LOW Jun 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ziftomenib BreakthroughPriorityFast Track+1 | newly diagnosed AML | Phase 1/2 | 2026-06-11 | 12-month OS rate 94% among NPM1-m AML patients; 71% among KMT2A-r AML patients; 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML; Median OS not reached in either NPM1-m or KMT2A-r population; High rates of MRD negativity among NPM1-m AML responders; 85% local CRc MRD-negativity rates in NPM1-m AML; 82% local CRc MRD-negativity rates in KMT2A-r AML; 79% marrow central MRD negativity among CRc responders in NPM1-m AML; 56% marrow central MRD negativity at the <0.01% threshold in NPM1-m AML Read More | Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML Read More | |
ziftomenib BreakthroughPriorityFast Track+1 | newly diagnosed AML | Phase 1/2 | 2026-06-11 | 12-month OS rate 94% among NPM1-m AML patients; 71% among KMT2A-r AML patients; 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML; Median OS not reached in either NPM1-m or KMT2A-r population; High rates of MRD negativity among NPM1-m AML responders; 85% local CRc MRD-negativity rates in NPM1-m AML; 82% local CRc MRD-negativity rates in KMT2A-r AML; 79% marrow central MRD negativity among CRc responders in NPM1-m AML; 56% marrow central MRD negativity at the <0.01% threshold in NPM1-m AML Read More | Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML Read More | |
ziftomenib BreakthroughPriorityFast Track+1 | newly diagnosed AML | Phase 1/2 | 2026-06-11 | 12-month OS rate 94% among NPM1-m AML patients; 71% among KMT2A-r AML patients; 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML; Median OS not reached in either NPM1-m or KMT2A-r population; High rates of MRD negativity among NPM1-m AML responders; 85% local CRc MRD-negativity rates in NPM1-m AML; 82% local CRc MRD-negativity rates in KMT2A-r AML; 79% marrow central MRD negativity among CRc responders in NPM1-m AML; 56% marrow central MRD negativity at the <0.01% threshold in NPM1-m AML Read More | Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KURA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KURA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-10-16 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KURAKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
Kura Oncology and Kyowa Kirin announced promising long-term results from the KOMET-007 trial, which evaluated ziftomenib combined with the 7+3 chemotherapy regimen in newly diagnosed AML patients. The trial reported a 94% overall survival rate for NPM1-m AML patients and a 71% rate for KMT2A-r AML patients, with high remission rates and favorable tolerability. These findings support the ongoing Phase 3 KOMET-017 study.
Read more →KURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Kura Oncology, Inc. has announced the granting of inducement awards consisting of nonstatutory stock options to four new employees as part of its 2023 Inducement Option Plan. This move, in accordance with Nasdaq Listing Rule 5635(c)(4), aims to attract talent by providing stock options that will vest over a four-year period. Each option has an exercise price of $9.04, matching the company’s closing stock price on June 1, 2026. The vesting schedule includes a one-year cliff followed by monthly vesting for the remaining period.
Read more →KURAKura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan Amended and Restated by the Board
Kura Oncology, Inc. has amended and restated its 2014 Equity Incentive Plan to enhance employee engagement and retention. This plan enables the granting of various awards including stock options and performance awards while allowing the Board to make necessary adjustments. The amendments also highlight Kura's intent to keep pace with the evolving needs of its workforce and market conditions. Stockholder approvals are recurring elements in the plan's amendment timeline, indicating a structured governance approach.
Read more →KURAKura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
Kura Oncology has presented promising preliminary Phase 1a data for darlifarnib in combination with adagrasib, showing significant response rates in various KRAS-mutant cancers. The company plans to initiate a platform study to evaluate darlifarnib across multiple therapies, starting with a combination in pancreatic cancer expected in early 2027. The findings reinforce darlifarnib's potential as a foundational treatment option in the evolving landscape of KRAS inhibitors.
Read more →KURAKura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology and Kyowa Kirin announced promising results from the KOMET-007 trial, evaluating ziftomenib combined with venetoclax and azacitidine in patients with relapsed/refractory NPM1-mutated acute myeloid leukemia. The combination showed an 87% overall response rate in venetoclax-naïve patients and was well tolerated. The findings highlight the potential of this combination therapy in addressing unmet needs in AML treatment.
Read more →KURA▼ -7.5%on this news
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
Kura Oncology reported promising results from the FIT-001 trial, showing that the combination of darlifarnib and adagrasib achieved significant tumor shrinkage in 77% of response-evaluable patients with KRAS G12C-mutated solid tumors. The objective response rates were notable, with 67% in pancreatic ductal adenocarcinoma, 50% in non-small cell lung cancer, and 29% in colorectal cancer. The findings suggest darlifarnib's potential as a precision therapy in overcoming resistance to existing treatments.
Read more →KURAKura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
Kura Oncology will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026. The management team will engage in a virtual fireside chat to discuss insights relevant to ASCO and EHA. The event will be accessible via a live webcast and archived replay on their website.
Read more →KURAKura Oncology Reports First Quarter 2026 Financial Results
Kura Oncology reported a successful first quarter of 2026, with KOMZIFTI generating $5.8 million in net revenue. The company noted strong early adoption among physicians and broad payer access covering over 12 million lives. Kura anticipates multiple data readouts this year to support ziftomenib as a key treatment in acute myeloid leukemia (AML). Financially, Kura holds $580.8 million in cash, expected to fund its AML program through pivotal trial results.
Read more →KURAKura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
Kura Oncology and Kyowa Kirin announced updated results from the Phase 1 KOMET-007 trial, which evaluated ziftomenib combined with traditional chemotherapy for treating newly diagnosed acute myeloid leukemia (AML). The trial showed high complete response rates of 90-96% and deep molecular response rates exceeding 80%. Durability of responses was encouraging, with a median follow-up of around 15 months for NPM1-m patients. The results will be discussed at the upcoming EHA Congress in Stockholm, highlighting the potential of ziftomenib in frontline AML therapy.
Read more →KURAKura Oncology to Participate in Bank of America Securities Healthcare Conference
Kura Oncology, a biopharmaceutical firm focused on precision cancer therapies, will participate in the Bank of America Securities 2026 Healthcare Conference. The management is set to engage in a fireside chat scheduled for May 13, 2026. The event will be accessible via a live webcast on the company's website.
Read more →KURAKura Oncology to Report First Quarter 2026 Financial Results
Kura Oncology will report its financial results for the first quarter of 2026 on May 12, 2026. Following the report, the management will host a conference call and webcast to discuss the results and provide updates on the company. Kura continues to focus on precision medicines for cancer treatment.
Read more →KURA▲ +8.3%on this news
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Kura Oncology reported promising preliminary data from the FIT-001 trial, indicating that the combination of darlifarnib and cabozantinib shows significant antitumor activity in patients with clear cell renal cell carcinoma (ccRCC) who were previously treated with cabozantinib. The study revealed a 44% objective response rate and a 94% disease control rate, with notable tumor shrinkage in 75% of patients. These findings suggest the combination may effectively overcome resistance in this challenging patient population.
Read more →KURAKura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Kura Oncology will present updated data on darlifarnib combined with cabozantinib for advanced clear cell renal cell carcinoma at the IKCS Europe 2026. This data builds on previous findings from the ESMO 2025 Congress, indicating the combination's potential to enhance treatment efficacy. The presentation is scheduled for April 17, 2026, alongside a virtual investor call.
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology reported its fourth quarter and full year 2025 financial results, highlighting the successful launch of KOMZIFTI, which generated $2.1 million in revenue shortly after FDA approval. The company anticipates multiple clinical milestones in 2026, supported by a strong financial position. However, it also faces challenges, including increased net losses and significant R&D expenses.
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Kura Oncology will report its fourth quarter and full year 2025 financial results on March 5, 2026. The announcement includes a conference call and webcast for discussion of the results and corporate updates. Kura is focused on precision medicines for cancer, with a notable pipeline including the FDA-approved KOMZIFTI.
Read more →KURAKura Oncology to Participate in Three Upcoming Investor Conferences
Kura Oncology, a biopharmaceutical company focused on precision cancer treatments, announced its participation in three upcoming investor conferences. The conferences include the TD Cowen Health Care Conference, the Leerink Partners Global Biopharma Conference, and the Barclays Global Healthcare Conference, all scheduled for March 2026. Live audio webcasts will be available on Kura's website.
Read more →KURAKura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones - Launched KOMZIFTI (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R
Kura Oncology has highlighted recent achievements, including the launch of KOMZIFTI (ziftomenib), an oral menin inhibitor approved for adults with relapsed or refractory acute myeloid leukemia (AML). The company reported $2.1 million in preliminary net product revenue since its commercial sales began in November 2025. Kura anticipates significant progress in 2026, driven by its extensive pipeline of therapies. However, KOMZIFTI is associated with serious adverse effects, including differentiation syndrome and QTc interval prolongation, which require careful monitoring in patients.
Read more →KURAKura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Kura Oncology and Kyowa Kirin reported promising data on the combination of KOMZIFTI (ziftomenib) with venetoclax and azacitidine for treating acute myeloid leukemia (AML). In newly diagnosed NPM1-m AML, 86% achieved composite complete remission, while 68% attained molecular MRD negativity. The combination was well tolerated, with no increased toxicity beyond venetoclax and azacitidine alone. Ongoing trials aim to further explore ziftomenib's potential in AML treatment.
Read more →KURA▲ +7.5%on this newsshared move
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology will host a virtual investor event on December 8, 2025, to discuss data on a triplet combination therapy involving ziftomenib, venetoclax, and azacitidine for acute myeloid leukemia. This event coincides with the 67th ASH Annual Meeting. The management team and lead investigators will present the findings.
Read more →KURAFirst U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
Kura Oncology announced the successful completion of the first U.S. commercial sale of KOMZIFTI, triggering a $135 million milestone payment from Kyowa Kirin. The drug, approved by the FDA for treating relapsed or refractory NPM1-mutated acute myeloid leukemia, represents a significant advancement in Kura's pipeline. The payment is expected to be received before year-end 2025.
Read more →KURAKOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin announced that KOMZIFTI (ziftomenib) has been added to the NCCN Guidelines as a Category 2A treatment for adults with relapsed or refractory AML with an NPM1 mutation. The drug received FDA approval on November 13, 2025, and demonstrated a 21.4% complete response rate in clinical trials. Despite its potential, KOMZIFTI carries risks, including differentiation syndrome and other serious adverse reactions.
Read more →KURAKura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
Kura Oncology and Kyowa Kirin announced the FDA's full approval of KOMZIFTI (ziftomenib) for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). This once-daily oral menin inhibitor addresses a significant unmet need in a patient population with historically poor outcomes. The approval is based on the KOMET-001 trial, demonstrating promising efficacy and safety. KOMZIFTI is expected to improve treatment options for patients with limited alternatives.
Read more →KURAKura Oncology to Participate in Upcoming Investor Conference
Kura Oncology, a clinical-stage biopharmaceutical company, will participate in the Jefferies Global Healthcare Conference on November 19, 2025. The event will feature a live audio webcast available on the company's website. Kura is dedicated to developing precision medicines for cancer, including its drug candidate ziftomenib for acute myeloid leukemia.
Read more →KURAKura Oncology Reports Third Quarter 2025 Financial Results
Kura Oncology reported its third quarter 2025 financial results, highlighting the ongoing FDA Priority Review for ziftomenib's New Drug Application. The company is advancing its Phase 3 KOMET-017 trials for ziftomenib in acute myeloid leukemia (AML) and plans to present findings at the upcoming ASH Annual Meeting. Kura's financial health is robust, with significant cash reserves to support ongoing programs.
Read more →KURAKura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
Kura Oncology has announced the receipt of a $30 million milestone payment from Kyowa Kirin following the dosing of the first patient in the KOMET-017 Phase 3 trials for ziftomenib. This marks the second milestone payment, bringing the total to $105 million. Kura anticipates further milestone payments totaling up to $315 million as the trials progress.
Read more →KURAKura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
Kura Oncology and Kyowa Kirin will present data from the KOMET-007 trial at the ASH 2025 Annual Meeting. The trial evaluates ziftomenib in combination with standard therapies for acute myeloid leukemia (AML). The presentations will include updated safety and clinical activity results for both newly diagnosed and relapsed/refractory AML patients. This research aims to enhance treatment options for AML patients.
Read more →KURAKura Oncology to Report Third Quarter 2025 Financial Results
Kura Oncology, Inc. has announced that it will report its third quarter financial results for 2025 on November 4, 2025, prior to the opening of U.S. financial markets. The company, focused on precision medicines for cancer treatment, will also host a conference call and webcast to discuss these results. This event highlights Kura's commitment to transparency and communication with its investors and the media.
Read more →KURA▲ +6.6%on this news· ran to +21% by day 1shared move
Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin
Kura Oncology has announced a $30 million milestone payment following the dosing of the first patient in its KOMET-017 Phase 3 clinical trials for ziftomenib, an investigational oral menin inhibitor. The trials aim to evaluate ziftomenib in patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia. This program is notable for being the only menin inhibitor initiative actively pursuing registrational trials across both intensive and non-intensive chemotherapy settings.
Read more →KURAKura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
Kura Oncology presented preliminary data on its farnesyl transferase inhibitors, darlifarnib and tipifarnib, at the 2025 ESMO Congress. The data highlighted a 50% objective response rate in renal cell carcinoma when darlifarnib was combined with cabozantinib. The company aims to address resistance pathways in cancer therapies through innovative combinations. A virtual investor event is scheduled for further discussions.
Read more →KURAK URA O NCOLOGY , I NC . 2023 I NDUCEMENT O PTION P LAN A DOPTED BY THE B OARD OF D IRECTORS : D ECEMBER 18, 2023 A MENDED BY THE B OARD OF D IRECTORS : D ECEMBER 16, 2024 A MENDED BY THE B OARD OF D IRECTORS : O CTOBER
Kura Oncology's Board of Directors has adopted an Inducement Option Plan designed to grant stock options to new employees. This plan seeks to entice suitable candidates as well as incentivize existing employees to enhance their efforts towards the company's success. The options under the plan are classified as Nonstatutory Stock Options and the administration will involve governed oversight by independent directors. The total share reserve allocated for the plan is fixed at 3,250,000 shares.
Read more →KURAKura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin have initiated the KOMET-007 clinical trial to evaluate ziftomenib, a menin inhibitor, in combination with chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) and FLT3/NPM1 mutations. This trial aims to address the high relapse rates and limited treatment options faced by these patients. Ziftomenib has received Breakthrough Therapy Designation from the FDA, highlighting its potential in AML treatment.
Read more →KURAKura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)
Kura Oncology and Kyowa Kirin have announced the dosing of the first patient in their pivotal Phase 3 KOMET-017 trial, investigating ziftomenib for frontline acute myeloid leukemia (AML). This trial includes two distinct arms testing ziftomenib in combination with both intensive and non-intensive therapies. The trials are designed to evaluate critical endpoints for potential U.S. regulatory approvals. The announcement underscores the urgent need for effective treatment options for patients diagnosed with AML, a challenging disease characterized by poor prognoses.
Read more →KURAKura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
Kura Oncology and Kyowa Kirin reported the publication of pivotal data from the KOMET-001 clinical trial that assesses ziftomenib for relapsed/refractory NPM1-mutated AML. The trial met its primary endpoint, showing a response rate of 22% in complete remission, which exceeds historical standards. Ziftomenib demonstrated significant clinical benefits while maintaining a favorable safety profile. The FDA has set a target action date of November 30, 2025, for ziftomenib's priority review as a treatment option for this challenging indication.
Read more →KURAKura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
Kura Oncology hosted an analyst/investor event highlighting the promising potential of KO-2806 (darlifarnib), a farnesyl transferase inhibitor, in overcoming drug resistance. The preclinical data suggests that KO-2806 can enhance the efficacy of several targeted therapies, including PI3Kα inhibitors and KRAS inhibitors, across various tumor types. Upcoming clinical data will be presented at ESMO Congress 2025, further elucidating KO-2806's role in combination treatments. The findings emphasize the importance of innovative strategies in oncology to improve patient outcomes.
Read more →KURA▲ +6%on this newsshared move
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
Kura Oncology will host two virtual investor and analyst events to discuss its farnesyl transferase inhibitor program. The first event on September 16 will focus on preclinical data showcasing the combination of FTIs with targeted therapies. The second event on October 18 will present clinical data from the ESMO Congress including insights from KO-2806, Kura's next-generation FTI, aiming to address cancer resistance mechanisms. The events underscore Kura's strategic leadership in cancer signaling pathway research and communication with stakeholders.
Read more →KURAKura Oncology Reports Second Quarter 2025 Financial Results – FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target actio
Kura Oncology has announced its second quarter 2025 financial results, highlighting the FDA's acceptance of the NDA for ziftomenib with a PDUFA target action date set for November 30, 2025. The company is preparing for commercialization and has reported promising results from clinical trials demonstrating the drug's effectiveness in treating relapsed or refractory NPM1-mutant AML. Additionally, Kura is focusing on further expanding its product pipeline and enhancing readiness across various operational facets. Despite facing significant net losses and rising expenses, the company's strategy positions it well for future growth.
Read more →KURAKura Oncology to Report Second Quarter 2025 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical firm, will report its financial results for the second quarter of 2025 on August 7, 2025. Following the report, the company's management is scheduled to host a webcast and conference call to discuss the results and give an update on corporate developments. Interested parties can access the call through provided dial-in numbers as well as a live webcast.
Read more →KURAFORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans
Kura's recent presentation outlines its ambitions in developing breakthrough therapies for cancer, notably focusing on the investigational drug Ziftomenib for acute myeloid leukemia (AML). The FDA has granted Priority Review for Ziftomenib based on promising results from a Phase 2 trial, with a target action date set for November 30, 2025. However, the company acknowledges several risks, including uncertainties in clinical trial outcomes and regulatory approvals, alongside the market potential underscored by a partnership with Kyowa Kirin. The presentation further highlights that a significant number of AML patients could benefit from the menin inhibitor Ziftomenib.
Read more →KURAKura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
Kura Oncology, in partnership with Kyowa Kirin, presented encouraging results from the KOMET-007 trial at the EHA2025 Congress. The trial evaluated ziftomenib, a selective menin inhibitor, combined with standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients. The results indicated high rates of complete remission and minimal residual disease negativity, alongside a favorable safety profile. Future Phase 3 studies, KOMET-017-IC and NIC, are planned to further assess ziftomenib's potential in AML treatment.
Read more →KURA▲ +10.7%on this news
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
Kura Oncology and Kyowa Kirin presented positive results for ziftomenib, an oral menin inhibitor, at the 2025 ASCO Annual Meeting, showing a 23% complete response rate in patients with relapsed/refractory NPM1-mutated AML. The trial demonstrated consistent efficacy across various patient subgroups and a favorable safety profile, with only 3% of patients discontinuing due to treatment-related adverse events. Ziftomenib is positioned for potential first approval in treating this patient population, with a PDUFA date set for November 30, 2025.
Read more →KURA▲ +10.7%on this newsshared move
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
Kura Oncology and Kyowa Kirin have announced that the FDA has accepted their New Drug Application for ziftomenib, aiming to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an NPM1 mutation. The application was based on strong results from the Phase 2 KOMET-001 trial, achieving its primary endpoint effectively. This NDA has been granted Priority Review status, with a target action date of November 30, 2025. If approved, ziftomenib could become the first menin inhibitor available for this specific cancer patient population.
Read more →KURAKura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting
Kura Oncology and Kyowa Kirin announced that an abstract detailing the KOMET-001 trial results of ziftomenib will be presented at the 2025 ASCO Annual Meeting. The trial focused on the drug's efficacy and safety for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia. Ziftomenib, which has received Breakthrough Therapy Designation from the FDA, achieved its primary endpoint and was reported to have a favorable safety profile. A virtual investor event is scheduled for June 2, 2025, to discuss the trial findings.
Read more →KURAKura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
Kura Oncology and Kyowa Kirin have announced that an abstract featuring clinical data from the KOMET-007 trial of ziftomenib has been accepted for an oral presentation at the EHA Congress. This Phase 1 trial explores ziftomenib's combination with chemotherapy for newly diagnosed patients with acute myeloid leukemia (AML). The upcoming presentation is expected to provide updated data that may support the drug's potential as a treatment option in this patient population. In addition to the oral presentation, other trial abstracts will also be presented at the congress.
Read more →KURAKura Oncology Reports First Quarter 2025 Financial Results – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data
Kura Oncology reported positive financial results for Q1 2025, highlighted by the submission of a New Drug Application (NDA) for ziftomenib aimed at treating adults with relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation. The company earned a $45 million milestone payment due to the NDA submission and reported a solid pro forma cash position. Furthermore, Kura announced the first patient dosing in a Phase 1 trial combining ziftomenib with imatinib for gastrointestinal stromal tumors. Significant clinical data presentations are scheduled at upcoming ASCO and EHA meetings.
Read more →KURAKura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
Kura Oncology has initiated dosing of the first patients in its Phase 1 clinical trial, KOMET-015, to evaluate ziftomenib in combination with imatinib for advanced gastrointestinal stromal tumors (GIST) after patients have failed imatinib treatment. The trial aims to assess the safety, tolerability, and preliminary antitumor activity of this combination therapy, building on the promising preclinical data that indicated substantial antitumor effects. Advanced GIST patients, who often face limited treatment options after standard care, may benefit from this innovative therapeutic approach.
Read more →KURAKura Oncology to Report First Quarter 2025 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, has announced that it will report its first quarter 2025 financial results on May 1, 2025, after U.S. market close. Management will follow the announcement with a conference call and webcast at 4:30 p.m. ET to discuss the results and provide an update on corporate activities. Details on accessing the call and the company's investor relations can be found on their website.
Read more →KURAKura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
Kura Oncology and Kyowa Kirin have announced the submission of a New Drug Application for ziftomenib to the FDA, targeted at treating adult patients with relapsed or refractory acute myeloid leukemia with a nucleophosmin 1 mutation. This investigational menin inhibitor has received multiple designations from the FDA aimed at expediting its review. Kura anticipates a response from the FDA regarding the NDA's completeness by the second quarter of 2025. The submission is seen as a key step toward offering a new therapeutic option for patients facing a disease with a high unmet medical need.
Read more →KURAKura Oncology to Participate in Stifel Targeted Oncology Forum
Kura Oncology, Inc. announced its participation in the upcoming Stifel 2025 Virtual Targeted Oncology Forum. CEO Troy Wilson will host a virtual fireside chat on April 8, 2025. An audio webcast of the event will be available, allowing investors and interested parties to access insights directly from the company. This participation highlights Kura's focus on precision medicines in cancer treatment.
Read more →KURAKura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
Kura Oncology has announced that an abstract featuring preclinical data for its farnesyl transferase inhibitor KO-2806 has been accepted for oral presentation at the AACR Annual Meeting in April 2025. The data supports the combination of KO-2806 with cabozantinib for the treatment of clear cell renal cell carcinoma (ccRCC). The company's Chief Scientific Officer emphasized the growing evidence for FTIs augmenting the effectiveness of targeted therapies. Results from the ongoing FIT-001 trial evaluating KO-2806 are expected to provide further insights this year.
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results – KOMET-001 registrational trial in R/R NPM1 -mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on
Kura Oncology has announced its fourth quarter and full year 2024 financial results, highlighting the successful achievement of the primary endpoint in the KOMET-001 trial for R/R NPM1-mutant AML. They have reached alignment with the FDA and EMA on critical aspects of the KOMET-017 trial protocol, which may allow for accelerated approval pathways. The company reported a net loss, but retains a robust cash balance of $727.4 million to support ongoing development and commercialization efforts for ziftomenib, with further data presentations expected in 2025.
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, announced that it will report its financial results for the fourth quarter and full year of 2024 on February 26, 2025, after U.S. market close. Management will host a conference call and webcast to discuss the results and provide updates. The company's ongoing commitment to precision medicines for cancer treatment underlines its dedication to addressing urgent medical needs in oncology.
Read more →KURAKura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
Kura Oncology and Kyowa Kirin announced successful topline results from the KOMET-001 trial, a Phase 2 study for ziftomenib in patients with relapsed/refractory NPM1-mutant AML. The trial achieved its primary endpoint, demonstrating strong efficacy, and the companies plan to submit a New Drug Application to the FDA by Q2 2025. Additionally, they are set to begin two Phase 3 trials assessing ziftomenib combined with various therapies for newly diagnosed AML patients, fueled by positive feedback from the FDA regarding accelerated approval opportunities. Full trial results are expected to be presented at a medical meeting in 2025.
Read more →KURAKura Oncology Announces Senior Executive Promotions
Kura Oncology has announced the promotion of Mollie Leoni, M.D. to Chief Medical Officer and Francis Burrows, Ph.D. to Chief Scientific Officer. These promotions follow Stephen Dale, M.D.'s decision to step down as CMO to prioritize personal health. Both Leoni and Burrows bring extensive experience and leadership to their new roles, which are expected to be pivotal for the company's ongoing cancer treatment programs, particularly the ziftomenib program. Kura continues to navigate the challenges of drug development with a strong focus on precision medicine for cancer care.
Read more →KURAK URA O NCOLOGY , I NC . 2023 I NDUCEMENT O PTION P LAN A DOPTED BY THE B OARD OF D IRECTORS : D ECEMBER 18, 2023 A MENDED BY THE B OARD OF D IRECTORS : D ECEMBER 16, 2024 1. G ENERAL . (a) Eligible Award Recipients. The
Kura Oncology, Inc. has announced the adoption of its 2023 Inducement Option Plan, which was amended by the Board of Directors in December 2024. The plan is designed to offer stock options to eligible candidates who meet specific criteria under Nasdaq rules, including those who have not previously served as employees or directors of the company. The initiative is intended to provide incentives for new employees, encouraging their contributions to the company’s growth and success. The Board will oversee the plan's administration and ensure compliance with Nasdaq regulations.
Read more →KURAKura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
Kura Oncology and Kyowa Kirin presented promising data for ziftomenib at the 2024 ASH Annual Meeting, showcasing its effectiveness in treating acute myeloid leukemia (AML). The Phase 1a trial showed a 100% complete remission rate in patients with NPM1 mutations and 83% in KMT2A alterations. Additionally, the drug was well tolerated with manageable side effects. The companies plan to expand their studies with a Phase 3 trial aimed at further validating ziftomenib's potential in frontline AML treatment.
Read more →KURAKura Oncology to Host Virtual Investor Event on December 9, 2024
Kura Oncology, a clinical-stage biopharmaceutical company, has announced a virtual investor event scheduled for December 9, 2024. The event will discuss the KOMET-007 combination trial of its oral menin inhibitor, ziftomenib, following updates presented at the 66th American Society of Hematology Annual Meeting. Key members of the management team, along with trial investigators, will be present to engage with investors. Access to the event will be available via phone and webcast.
Read more →KURAKura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Kura Oncology, Inc. (NASDAQ: KURA) has announced its participation in the JMP Securities Hematology and Oncology Summit scheduled for December 2, 2024. CEO Troy Wilson will take part in a virtual fireside chat, aimed at discussing the company's approach to precision cancer medicines. The event represents an opportunity for Kura to engage with investors and industry stakeholders. A live audio webcast will be available on the company's website for those interested in attending.
Read more →KURAKura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Kura Oncology and Kyowa Kirin have formed a global strategic collaboration to develop and commercialize ziftomenib, an investigational treatment for acute myeloid leukemia. Kura will receive an upfront payment of $330 million and potentially up to $1.2 billion in milestone payments. Under the agreement, Kura will lead U.S. development and commercialization, while Kyowa Kirin will handle those aspects outside the U.S. The collaboration aims to advance ziftomenib through clinical trials and towards commercialization, capitalizing on both companies' strengths and resources.
Read more →KURAKura Oncology Reports Third Quarter 2024 Financial Results – Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet On
Kura Oncology reported its third-quarter 2024 financial results, highlighting several key developments. The company anticipates topline data from a registration-directed trial of ziftomenib in relapsed/refractory NPM1-mutant AML in early 2025. Additionally, encouraging Phase 1 trial results for ziftomenib combined with standard therapies were noted, with significant safety and tolerability profiles. Kura continues to maintain a strong financial position, with cash resources projected to sustain its operations into 2027.
Read more →KURAKura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Kura Oncology announced that updated data from the KOMET-007 combination trial of ziftomenib will be presented at the upcoming ASH Annual Meeting. The trial focuses on patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML). Initial results indicate promising safety and tolerability for ziftomenib when combined with standard therapies. The presentations are scheduled for December 7 and 8, 2024, in San Diego, showcasing both early and continued responses in clinical cohorts.
Read more →KURAKura Oncology to Report Third Quarter 2024 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, announced it will report its third quarter 2024 financial results on November 7, 2024. The report will be followed by a conference call and webcast at 4:30 p.m. ET to discuss the results and offer a corporate update. The event can be accessed by domestic and international callers, and additional details will be available on the company's investor relations website.
Read more →KURAKura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
Kura Oncology announced promising preclinical data for ziftomenib, a menin inhibitor, for treating advanced gastrointestinal stromal tumors (GIST). The data demonstrates robust synergy with imatinib, showing durable antitumor activity in various GIST models. Kura plans to initiate a proof-of-concept study in 2025 following FDA clearance for ziftomenib's IND application. This combination aims to address the unmet needs of patients who have progressed on imatinib therapy.
Read more →KURAKura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
Kura Oncology has announced it will present new preclinical data at the EORTC-NCI-AACR Symposium, highlighting the combination of its farnesyl transferase inhibitor, KO-2806, with KRAS G12C and pan-RAS inhibitors. The findings indicate that KO-2806 could enhance the effectiveness of treatments for cancers driven by KRAS mutations, specifically in non-small cell lung cancer and colorectal cancers. The presentations will take place on October 25, 2024, and emphasize KO-2806's potential to overcome drug resistance in existing therapies.
Read more →KURAKura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
Kura Oncology, Inc. announced the publication of its KOMET-001 Phase 1 study results for ziftomenib in The Lancet Oncology. The study indicates ziftomenib's encouraging benefits in treating NPM1-mutant acute myeloid leukemia, with results showing significant clinical activity and manageable toxicity. The publication helps expand the evidence supporting this investigational drug's efficacy in a high unmet need clinical context. Kura is gearing up for its pivotal Phase 2 registration-directed trial while reporting topline results expected in early 2025.
Read more →KURAFostering a Workplace Place for Innovators to Thrive
Kura Oncology has been recognized as a leading workplace for innovators by Fast Company. The company emphasizes a supportive environment for creative minds, highlighted by its proactive engagement with the FDA's Project Optimus. Kura also undertook a pay equity analysis to ensure fair compensation across demographics, reinforcing its commitment to innovation and inclusivity.
Read more →KURAKura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
Kura Oncology announced the appointment of Dr. Michael Vasconcelles to its Board of Directors. With over 25 years of experience in oncology drug development, Dr. Vasconcelles is expected to contribute significantly to Kura's precision medicine initiatives, particularly its menin inhibitor and farnesyl transferase inhibitor programs. The appointment comes at a pivotal moment for the company, as it seeks to advance new cancer therapies through clinical trials and toward commercialization.
Read more →KURAKura Oncology to Participate in Cantor Global Healthcare Conference
Kura Oncology, a clinical-stage biopharmaceutical company focusing on cancer treatment, will participate in the Cantor Global Healthcare Conference in New York. CEO Troy Wilson is set to join a fireside chat scheduled for September 17, 2024, at 1:20 p.m. ET. The event will allow Kura to showcase its commitment to precision medicine in oncology. A live audio webcast will be available on the company's website, along with an archived replay post-event.
Read more →KURAKura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology announced that the FDA has cleared its Investigational New Drug (IND) application for ziftomenib, a menin inhibitor, to treat advanced gastrointestinal stromal tumors (GIST). The company plans to start a Phase 1 clinical trial combining ziftomenib with imatinib, aiming to address treatment options for patients who have developed resistance to imatinib. This marks the first IND clearance of a menin inhibitor for GIST, highlighting its potential to improve patient outcomes in a challenging therapeutic area.
Read more →KURAKura Oncology Reports Second Quarter 2024 Financial Results – Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 – – Breakthrough Therapy Design
Kura Oncology reported its second-quarter 2024 financial results, highlighting significant advancements in its clinical programs. Ziftomenib received Breakthrough Therapy Designation for treating relapsed/refractory NPM1-mutant AML, with topline data expected in early 2025 from trials indicating promising efficacy. The company also announced the start of a Phase 1b expansion study for ziftomenib, alongside positive financial status with $491.5 million in cash reserves. However, the increase in net losses and rising operational costs point to ongoing financial challenges as the company moves forward.
Read more →KURAKura Oncology to Report Second Quarter 2024 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, will report its second quarter 2024 financial results on August 8, 2024, after U.S. markets close. The company has scheduled a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. This initiative reflects Kura's commitment to transparency and investor communication as it advances its cancer treatment initiatives.
Read more →KURAKura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
Kura Oncology has presented promising preclinical data at the American Diabetes Association's Scientific Sessions, highlighting the potential of their menin inhibitor, ziftomenib, in treating type 2 diabetes. The data indicates that ziftomenib improves insulin production and sensitivity, while also maintaining glycemic control after treatment cessation. This development aims to address the significant unmet needs for better therapies in diabetes management, as many patients struggle to achieve glycemic control. Kura continues to explore further advancements in menin inhibitors for metabolic diseases.
Read more →KURA(qq) “ Restricted Stock Award Agreement ” means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each R
Kura Oncology, Inc. has undergone several amendments to its 2014 Equity Incentive Plan. The plan aims to attract and retain employees, directors, and consultants by providing various stock award options. The Board of Directors will administer the plan and has the authority to amend its provisions and terms. Recent amendments have included changes approved by stockholders to ensure compliance with various laws and to expand the plan's benefits.
Read more →KURAKura Oncology to Participate in Jefferies Global Healthcare Conference
Kura Oncology, a clinical-stage biopharmaceutical company focused on cancer treatments, will participate in the upcoming Jefferies Global Healthcare Conference. CEO Troy Wilson is scheduled to engage in a virtual fireside chat on June 5, 2024, at 3:00 p.m. ET. This event provides an opportunity for the company to share insights and updates with investors, enhancing transparency in their operations.
Read more →KURAKura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
Kura Oncology has successfully completed the enrollment of 85 patients in its Phase 2 clinical trial, KOMET-001, evaluating the efficacy of ziftomenib for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). This milestone was reached in less than 16 months, indicating a strong need for effective treatment options in this area. The company anticipates reporting topline data in early 2025, bolstered by a Breakthrough Therapy Designation granted by the FDA to expedite the drug's review process. Ziftomenib targets a significant unmet need, as current treatment options for NPM1-mutant AML are limited.
Read more →KURAKura Oncology Reports First Quarter 2024 Financial Results – Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on tra
Kura Oncology has reported its financial results for the first quarter of 2024, highlighting the receipt of Breakthrough Therapy Designation for ziftomenib in treating NPM1-mutant AML. The company is on track to complete enrollment for its registration-directed trial by mid-2024 and has also reported promising data from combination trials involving ziftomenib. However, Kura faces challenges as its net loss has increased, reflecting higher operational expenses. The company's current financial standing supports its ongoing research and development initiatives until at least 2027.
Read more →KURAKura Oncology to Report First Quarter 2024 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, will report its first quarter 2024 financial results on May 2, 2024. The announcement was made on April 25, 2024, and follows the company's commitment to developing precision medicines for cancer. Management will host a webcast and conference call at 4:30 p.m. ET to discuss the results and provide an update on corporate activities. This event underscores Kura's ongoing communication with its investors and stakeholders.
Read more →KURAKura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Kura Oncology has announced that its investigational drug, ziftomenib, has received Breakthrough Therapy Designation from the FDA for treating relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). This designation highlights the drug's potential to fulfill a significant unmet medical need, as there are currently no approved targeted therapies for this condition. Ziftomenib showed encouraging safety and efficacy in early clinical trials, achieving a 35% complete remission rate when administered at the recommended dose. Kura aims to complete its registration-directed trial by mid-2024.
Read more →KURA▲ +7.9%on this news
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Kura Oncology has announced that the first patient has been dosed in a Phase 1 trial of KO-2806, a next-generation farnesyl transferase inhibitor, in combination with cabozantinib for treating clear cell renal cell carcinoma. This trial marks a significant milestone as it explores the efficacy of the combination therapy to overcome resistance mechanisms commonly encountered in targeted treatments. The company anticipates further developments, including dosing in combination with adagrasib for KRASG12C-mutant non-small cell lung cancer in the upcoming quarter.
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results – Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of dif
Kura Oncology has reported strong preliminary results from the KOMET-007 trial of ziftomenib in treatment of NPM1-m and KMT2A-r acute myeloid leukemia (AML), including a 100% complete remission rate among newly diagnosed patients. The company has also begun dosing the first patient in its KOMET-008 trial, which aims to explore ziftomenib in combination with other therapies. With significant financial backing and ongoing trial expansion, Kura emphasizes its commitment to addressing the unmet need in acute leukemia treatment.
Read more →KURAKura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
Kura Oncology has initiated dosing for the first patient in its KOMET-008 trial, aiming to evaluate ziftomenib, a menin inhibitor, in combination with other therapies for acute myeloid leukemia (AML). This Phase 1 trial targets patients with NPM1 mutations or KMT2A rearrangements, who have limited treatment options. The combination therapy, including gilteritinib, seeks to provide better safety and efficacy for patients with poor prognoses in relapsed or refractory cases. Kura's research highlights the urgent need for effective therapies in AML, particularly those addressing genetic mutations that complicate treatment outcomes.
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, announced it will report its fourth quarter and full year 2023 financial results on February 27, 2024. The financial report will be followed by a corporate update via a webcast and conference call. Interested parties can access the live call and future replays through the company's investor relations segment on their website.
Read more →KURAScrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
The article discusses anticipated trends in clinical trials for the biopharma sector in 2024, emphasizing the impact of digital and data advancements. It suggests that these innovations will drive significant changes in how clinical trials are conducted. Insights from industry experts are provided to forecast future developments.
Read more →KURA▲ +12.1%on this newsshared move
DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Preliminary Data from KOMET-007
Kura Oncology presented preliminary data from the KOMET-007 trial, highlighting the potential of Ziftomenib as a cornerstone therapy for acute myeloid leukemia (AML). The initial findings indicate promising clinical activity, with a strong safety profile and rapid patient enrollment showing significant investigator enthusiasm. However, the company acknowledges the risks associated with regulatory approvals and potential disruptions due to the COVID-19 pandemic. Overall, Ziftomenib is positioned to enhance treatment options for AML patients.
Read more →KURA▲ +12.1%on this newsshared move
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
Kura Oncology has reported promising preliminary data from their KOMET-007 trial, showcasing ziftomenib's significant efficacy in treating acute myeloid leukemia (AML). The drug achieved a 100% complete remission rate in newly diagnosed patients using 7+3 therapy, and demonstrated a 56% complete response rate in refractory/relapsed patients treated with venetoclax/azacitidine. Importantly, ziftomenib was well-tolerated, with no differentiation syndrome events reported. With continued patient enrollment and plans for further studies, Kura Oncology believes this could enhance treatment outcomes for AML patients.
Read more →KURA▲ +46.1%on this news
Kura Oncology Announces Oversubscribed $150 Million Private Placement Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital Pro forma cash, cash equivalents a
Kura Oncology has announced an oversubscribed private placement funding of $150 million from existing investors, including EcoR1 Capital and Suvretta Capital. The capital raised will provide a financial runway into 2027, supporting the company's research and development efforts for its clinical-stage candidates. A virtual investor event will be hosted on January 30, 2024, to highlight preliminary data for ziftomenib, a treatment targeting acute myeloid leukemia. The financing agreement is expected to close around January 26, 2024, pending customary conditions.
Read more →KURAPharmaVoice’s Crystal Ball: Perspectives on the financial future
Industry leaders discuss the financial outlook for pharma and biotech in 2024, highlighting challenges such as high interest rates, economic recession, and the impact of the Inflation Reduction Act. Despite these hurdles, there are signs of potential recovery, particularly in weight loss drug markets and the possibility of generalist investors returning. The article emphasizes the need for strategic financing and adaptation in the evolving landscape.
Read more →KURA▲ +8.9%on this news
K URA O NCOLOGY , I NC . 2023 I NDUCEMENT O PTION P LAN A DOPTED BY THE B OARD OF D IRECTORS : D ECEMBER 18, 2023 1. G ENERAL . (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under t
Kura Oncology, Inc. has adopted a new inducement option plan intended to attract eligible employees by offering stock options as incentives. This plan is compliant with Nasdaq Marketplace Rules, meaning it follows necessary regulations for inducement grants. Only individuals who have not recently served as employees or directors will be eligible for the grants. The Board of Directors will oversee the plan, ensuring an independent evaluation of award grants.
Read more →KURA▼ -6.7%on this newsshared move
Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML
Dr. Erba provided insights on the KOMET-001 Phase 1b trial, focusing on the safety and tolerability of ziftomenib, a menin inhibitor, for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The discussion highlights the importance of ongoing clinical trials in assessing new treatment options for this patient population.
Read more →KURADr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML
The article discusses Dr. Erba's insights regarding the KOMET-007 Phase 1 trial. It focuses on the investigation of ziftomenib in combination with standard treatments for newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) with specific genetic mutations. However, the content does not provide detailed findings or outcomes from the trial.
Read more →KURADr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007
The article discusses Dr. Erba's explanation of the various combinations that the KOMET-008 trial will evaluate, highlighting its differences from the previous KOMET-007 trial. However, specific details about the combinations or the trials themselves are not provided in the text.
Read more →KURA“Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD
The article features a quote from Harry Erba, MD, PhD, discussing Project Optimus, which emphasizes the importance of optimal biological dosing over maximally tolerated dosing. However, the article does not provide further details or context about the project or its implications.
Read more →KURADr. Erba provides an overview of the KOMET clinical trial program
The article mentions Dr. Erba providing an overview of the KOMET clinical trial program. However, it lacks specific details about the trial or its implications. The content is primarily focused on confirming user access to the site, without offering substantial information on the clinical trial itself.
Read more →KURAKura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
Kura Oncology's menin inhibitor, ziftomenib, has been selected for the Leukemia & Lymphoma Society's PedAL Master Clinical Trial focused on pediatric acute leukemia. The trial aims to provide more effective therapies for children with specific genetic mutations associated with relapsed or refractory leukemia. Kura plans to supply ziftomenib for the study, alongside collaboration with the Princess Máxima Center for Pediatric Oncology. Despite previous encouraging results, potential challenges remain regarding the drug's efficacy and regulatory approval.
Read more →KURAManufacturing And Supply Chain: Making Space Between A Rock And A Hard Place
The article discusses the importance of internal manufacturing and oversight by Contract Development and Manufacturing Organizations (CDMOs) in the biopharma sector. It highlights the ongoing supply chain shortages expected next year and suggests that collaboration with government regulators can help mitigate these issues. Additionally, it notes that some companies have turned shortages into opportunities.
Read more →KURAThe Promise of Precision Oncology, Troy Wilson, President & CEO, Kura Oncology
Troy Wilson, President and CEO of Kura Oncology, discusses his leadership experiences and the responsibilities of a CEO compared to a board member. He highlights the importance of a productive board and shares insights on recruiting talent for both teams and boards. Wilson also addresses the future of cancer drug development and Kura's ongoing projects.
Read more →KURAKura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
Kura Oncology, a biopharmaceutical company focused on cancer treatment, announced its participation in the JMP Securities Hematology and Oncology Summit. Scheduled for December 5, 2023, the event will feature a virtual fireside chat with CEO Troy Wilson. Investors can access a live audio webcast through Kura's website, with a replay available afterward. This engagement underscores Kura's commitment to sharing insights on precision medicine in oncology.
Read more →KURA▲ +5.4%on this news· ran to +16% by day 3
Kura Oncology’s CEO gives an update on Q3 earnings
The article discusses Kura Oncology's Q3 earnings update but lacks specific financial details. It primarily focuses on a verification process for site security, which detracts from the core news. As a result, readers do not gain insights into the company's performance or future outlook.
Read more →KURA▲ +5.4%on this news· ran to +16% by day 3shared move
Kura Oncology Reports Third Quarter 2023 Financial Results – Completion of enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML expected by mid-2024 – – Preliminary da
Kura Oncology has reported its financial results for Q3 2023 and announced significant progress in their clinical trials. The company expects to complete enrollment of the KOMET-001 trial for ziftomenib in NPM1-mutant AML by mid-2024. Preliminary data from the KOMET-007 trial is anticipated in early Q1 2024, highlighting the potential of ziftomenib in combination therapies. Additionally, Kura has initiated a clinical collaboration with Mirati Therapeutics for KO-2806 in KRASG12C-mutated NSCLC, showcasing its strategic direction in oncology.
Read more →KURAKura Oncology to Report Third Quarter 2023 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical firm, has announced that it will report its financial results for the third quarter of 2023 on November 2, 2023, after U.S. markets close. The company's management will hold a conference call and webcast at 4:30 PM ET to discuss these results and provide corporate updates. Investors and interested parties can access the call via telephone or through a live webcast. Details for accessing the call and a replay will also be available on the company's website.
Read more →KURAKura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
Kura Oncology has initiated the FIT-001 Phase 1 trial for KO-2806, a new farnesyl transferase inhibitor aimed at treating advanced solid tumors. The trial will assess KO-2806 both as a monotherapy and in combination with other targeted therapies, particularly for KRASG12C-mutant non-small cell lung cancer and clear cell renal cell carcinoma. The company has expressed optimism about the drug's potential, highlighting its enhanced properties aimed at addressing high unmet medical needs in cancer treatment.
Read more →KURAKura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
Kura Oncology announced promising results from its AIM-HN study of tipifarnib for patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC). The study demonstrated meaningful antitumor activity, with a complete response in one patient and significant partial responses noted. Tipifarnib showed a manageable safety profile, suggesting it could fill a critical gap for this patient population that currently lacks targeted therapies. The results will be shared during a late-breaking session at the upcoming ESMO Congress.
Read more →KURAKura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Kura Oncology has announced that three abstracts related to its next-generation farnesyl transferase inhibitor, KO-2806, have been accepted for poster presentation at the AACR-NCI-EORTC International Conference on October 13, 2023. The presentations will focus on preclinical data showing KO-2806's ability to enhance antitumor activity when combined with various targeted therapies. The findings suggest potential implications for treating difficult cancers through improved signaling pathways.
Read more →KURADr. Fathi presents the latest KOMET-001 data
The article titled 'Dr. Fathi presents the latest KOMET-001 data' is currently inaccessible due to a verification check. As a result, no specific details or findings from the KOMET-001 study are available for review. This limitation hinders the ability to assess the significance of the presented data.
Read more →KURAPharmaVoice 100 Top Industry Leaders: Teresa Bair, J.D.
The article highlights Teresa Bair, J.D., as one of the top industry leaders in the PharmaVoice 100. It features her contributions and impact within the biopharma sector. The focus is on her leadership and achievements, showcasing her role in advancing the industry.
Read more →KURAKura Oncology to Participate in Cantor Global Healthcare Conference 2023
Kura Oncology announced its participation in the Cantor Global Healthcare Conference 2023. The event will take place in New York on September 26, where CEO Troy Wilson is scheduled to participate in a fireside chat. A live audio webcast of the session will be available on Kura's website, allowing investors and stakeholders to engage with the company's insights into cancer treatment innovations.
Read more →KURAEvaluating ziftomenib in combinations for patients who are newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML
The article discusses the evaluation of ziftomenib in combination therapies for patients with newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML. However, the content is limited and does not provide detailed insights or findings regarding the study or its implications.
Read more →KURAKura Oncology Appoints Brian Powl as Chief Commercial Officer
Kura Oncology has appointed Brian Powl as Chief Commercial Officer, who brings over two decades of experience in hematology and oncology. Powl's previous roles include leading commercial efforts at Fate Therapeutics and significant positions at Celgene Corporation. His expertise aligns with Kura's strategic goals for the menin inhibitor ziftomenib, which is anticipated to bring substantial benefits in treating acute myeloid leukemia. The company is poised for important milestones as it aims to enhance its commercial presence in the biotech sector.
Read more →KURANPM1 mutations in acute myeloid leukemia: actionable mutations to inform treatment decisions with clinical trials
The article discusses NPM1 mutations in acute myeloid leukemia and their implications for treatment decisions in clinical trials. It emphasizes the importance of identifying actionable mutations to guide therapy. However, the article does not provide specific details or findings.
Read more →KURAMechanism of action for investigational menin inhibitors, including ziftomenib
The article appears to be incomplete and does not provide relevant information about the mechanism of action for investigational menin inhibitors, including ziftomenib. It primarily consists of a verification prompt and does not delve into the subject matter as expected.
Read more →KURAKura Oncology Reports Second Quarter 2023 Financial Results – Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed i
Kura Oncology reported its second-quarter financial results, highlighting strong enrollment in the ziftomenib trial for NPM1-mutant AML, which exceeded projections. The latest clinical data presented at the EHA Annual Congress demonstrated a notable response rate for ziftomenib, reinforcing its potential in AML therapy. The company also has an substantial cash position of $477 million, expected to sustain operational activities through mid-2026. However, Kura faced a net loss of $37.2 million during the quarter, accompanied by rising research and development costs.
Read more →KURAKura Oncology to Report Second Quarter 2023 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, announced it will report its second quarter financial results on August 3, 2023, after U.S. markets close. A webcast and conference call will follow to discuss these results and provide a corporate update. Kura is advancing its pipeline, including the drug ziftomenib for treating AML, and is preparing to start multiple Phase 1 trials for its candidates. Their focus remains on precision medicines for cancer.
Read more →KURA▼ -6.8%on this newsshared move
San Diego Business Journal Leaders of Influence in Life Sciences 2023 Honorees
The San Diego Business Journal has announced the 2023 Leaders of Influence in Life Sciences honorees. This recognition celebrates individuals who have made significant contributions to the life sciences sector, promoting innovation and collaboration within the industry. The event underscores the importance of leadership in advancing healthcare and biopharma.
Read more →KURA▼ -9.8%on this news
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Kura Oncology, a clinical-stage biopharmaceutical company, announced the pricing of a public offering of common stock and pre-funded warrants, aiming to raise approximately $100 million. The offering consists of 5,660,871 shares of common stock and 3,034,782 pre-funded warrants, priced at $11.50 and $11.4999 respectively. The offering proceeds will primarily support ongoing clinical trials for its drug candidates. The transaction is expected to close around June 16, 2023, pending customary conditions.
Read more →KURAKura Oncology Announces Commencement of Public Offering of Common Stock and Pre-Funded Warrants
Kura Oncology has announced the commencement of a public offering to sell $100 million worth of its common stock or pre-funded warrants. The offering is subject to market conditions and will include a 30-day option for underwriters to purchase additional shares. Kura is noted for its commitment to precision cancer treatments, with ongoing clinical trials for its drug candidates. However, there is uncertainty regarding the completion and specific terms of the offering.
Read more →KURAThis presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines fo
Kura Oncology presented forward-looking statements regarding its development of precision medicines, specifically ziftomenib for treating acute myeloid leukemia (AML). The presentation highlighted encouraging clinical data from the Phase 1b KOMET-001 study, which suggests ziftomenib demonstrates promising efficacy and safety in patients with NPM1-mutant AML. Despite positive indicators, the company acknowledged several risks associated with clinical trials and regulatory approvals. Overall, ziftomenib is positioned as a potentially transformative therapy in the AML treatment landscape.
Read more →KURAKura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress
Kura Oncology presented promising late-breaking clinical data for ziftomenib, a menin inhibitor, showing a 35% complete response rate among patients with relapsed/refractory NPM1-mutant AML at a recent congress. The median duration of response was reported at 8.2 months. The trial's enrollment continues to exceed projections, highlighting the drug's potential in addressing a significant unmet need in AML treatment. Ziftomenib is being evaluated further in a Phase 2 registration-directed trial, with plans for upcoming combination studies.
Read more →KURAKura Oncology Announces Late-Breaking Abstract Accepted for Oral Presentation at the 2023 European Hematology Association (EHA) Congress
Kura Oncology announced that a late-breaking abstract regarding its menin inhibitor, ziftomenib, has been accepted for oral presentation at the 2023 European Hematology Association Congress. The abstract will cover updated data from a Phase 1 trial focused on treating adults with relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). The presentation is scheduled for June 11, 2023, and will be complemented by a virtual investor event on June 12, showcasing insights from the company management and trial investigators. Kura continues to develop ziftomenib and expand its pipeline of precision cancer medicines.
Read more →KURAKura Oncology to Participate in Two Upcoming Investor Conferences
Kura Oncology, a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences. CEO Troy Wilson will engage in fireside chats at the TD Cowen 4th Annual Oncology Innovation Summit on May 30, and at the Jefferies Healthcare Conference on June 7. The company is focused on developing precision medicines for cancer treatment, with an active pipeline that includes ziftomenib for AML and tipifarnib for head and neck squamous cell carcinoma.
Read more →KURAKura Oncology Reports First Quarter 2023 Financial Results – Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 reg
Kura Oncology reported its Q1 2023 financial results, highlighting promising developments in the Phase 1 trial of ziftomenib for NPM1-mutant acute myeloid leukemia (AML). The company is set to present updated data at the upcoming European Hematology Association Congress. Additionally, site activation and patient enrollment in Phase 2 trials exceed expectations, and Kura plans to initiate several combination studies this quarter. The financial report also indicated a net loss of $34.1 million, raising alerts regarding expense management amidst promising clinical developments.
Read more →KURAKura Oncology to Participate in JMP Securities Life Sciences Conference
Kura Oncology, a clinical-stage biopharmaceutical company, will participate in the JMP Securities Life Sciences Conference in New York on May 16, 2023. The CEO, Troy Wilson, is scheduled for a fireside chat where he will discuss the company's advancements in precision medicines for cancer treatment. Kura's pipeline includes ziftomenib, aimed at treating acute myeloid leukemia, and ongoing trials for various cancer indications. The event will be available via a live audio webcast on Kura's investor website.
Read more →KURAKura Oncology to Report First Quarter 2023 Financial Results
Kura Oncology announced it will report its first quarter 2023 financial results on May 10, 2023, after market close. A webcast and conference call will follow to discuss the results and provide updates on the company's operations. The company is actively involved in clinical trials for its drug candidates, including ziftomenib and tipifarnib, targeting specific cancer types.
Read more →KURABackground: The menin and histone-lysine- N -methyltransferase 2A ( KMT2A ) protein complex is an essential epigenetic regulator of genes critical for maintenance of multiple genetic subtypes of leukemia. This complex is
The article discusses the Phase 1/2 study KOMET-001 examining ziftomenib in NPM1 mutant and KMT2A rearranged relapsed/refractory AML patients. Results show a 30% complete remission rate and significant clinical activity in heavily pretreated populations. Most patients experienced adverse events, with 85% reporting Grade 3 events, but the safety profile remains consistent with previous reports. Ongoing studies will further evaluate ziftomenib's efficacy and safety in this patient demographic.
Read more →KURAKura Oncology to Participate in Stifel Targeted Oncology Days
Kura Oncology, Inc. announced its participation in the Stifel 2023 Targeted Oncology Days, scheduled for April 25, 2023. CEO Troy Wilson will take part in a virtual fireside chat to discuss the company's advancements in cancer treatment. Kura's pipeline includes drugs aimed at various genetically defined cancer types, and it is actively enrolling patients in key clinical trials. The event aims to enhance investor engagement and awareness of Kura's initiatives.
Read more →KURAKura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
Kura Oncology reported promising preclinical data showcasing the synergistic effects of farnesyl transferase inhibitors (FTIs) in combination with targeted therapies against various solid tumors. Presentations at the AACR Annual Meeting emphasized the potential of tipifarnib in enhancing treatment efficacy for clear cell renal cell carcinoma (RCC) and KRASG12C mutant non-small cell lung cancer (NSCLC). The company is set to initiate the Phase 1 dose-escalation trial (FIT-001) for KO-2806, a next-generation FTI, later this year, aiming to assess its safety and effectiveness as a monotherapy and in combination treatments.
Read more →KURAKura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
Kura Oncology announced the acceptance of two abstracts for presentation at the AACR Annual Meeting. The presentations will focus on preclinical data related to the combination of farnesyl transferase inhibitors with KRASG12C inhibitors and tyrosine kinase inhibitors. Kura also highlighted progress with its next-generation farnesyl transferase inhibitor, KO-2806, including FDA clearance and plans for a Phase 1 trial. The meeting will take place from April 14-19 in Orlando, with presentations scheduled for April 16.
Read more →KURAKura Oncology to Participate in Upcoming Investor Conferences
Kura Oncology announced its upcoming participation in investor conferences where CEO Troy Wilson will present on various discussions. The events include a Corporate Panel at the Cowen Health Care Conference and a fireside chat at the Barclays Global Healthcare Conference. The company highlighted its commitment to precision medicines for cancer treatment and provided updates on its clinical trials, including Ziftomenib, currently enrolling patients in a Phase 2 trial for AML. Live webcasts will be accessible on Kura's website for those interested in following the discussions.
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results – Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose –
Kura Oncology has reported its fourth quarter and full year 2022 financial results, highlighting promising Phase 1 data for ziftomenib, which shows a 30% complete response rate in patients with NPM1-mutant acute myeloid leukemia (AML). The company received FDA clearance for its Investigational New Drug application for KO-2806 and secured a $25 million strategic equity investment from Bristol Myers Squibb. With $438 million in cash available, Kura expects to advance its clinical trials into 2025, announcing plans to initiate combination studies and share updated data later in 2023.
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results
Kura Oncology, a clinical-stage biopharmaceutical company, announced its fourth quarter and full-year financial results will be reported on February 23, 2023. The company plans to host a webcast and conference call to discuss these results and provide a corporate update. Kura's drug pipeline includes promising candidates such as ziftomenib and tipifarnib, which are being investigated for various cancer indications.
Read more →KURAKura Oncology Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia
Kura Oncology has initiated the dosing of the first patients in its KOMET-001 Phase 2 trial for ziftomenib, a novel menin inhibitor targeting NPM1-mutant acute myeloid leukemia (AML). The Phase 1 trial previously indicated a 30% complete response rate at the recommended dose. The new trial aims to further evaluate ziftomenib's effectiveness and safety among 85 patients across the U.S. and Europe. The investigation is part of a broader effort to address the high unmet medical need in relapsed or refractory AML, especially in patients with NPM1 mutations.
Read more →KURAKura Oncology to Participate in SVB Securities Global Biopharma Conference
Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the virtual SVB Securities Global Biopharma Conference, slated for February 14, 2023. CEO Troy Wilson will engage in a fireside chat as part of the event. The company is focused on the development of precision medicines for cancer treatment and has several promising drug candidates in its pipeline, including a Breakthrough Therapy Designation drug for HRAS-mutant head and neck squamous cell carcinoma. Additionally, Kura is advancing its next-generation farnesyl transferase inhibitor through initial clinical studies.
Read more →KURAKura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase Inhibitor
Kura Oncology announced that the FDA has cleared its IND application for KO-2806, a next-generation farnesyl transferase inhibitor aimed at treating advanced solid tumors. The upcoming Phase 1 study will assess KO-2806 as a monotherapy and in combination therapies, with initiation expected in the third quarter of 2023. This development marks a key step for Kura, known for its focus on precision medicines in oncology, as they advance their pipeline targeting challenging cancer types.
Read more →KURA▼ -12.8%on this news
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML – – Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg – – 600 mg determined as recommended Phase 2 dose for ziftomenib in
Read more →KURAKura Oncology to Host Investor Event on December 10, 2022
SAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will host an investor event featuring members
Read more →KURAKura Oncology Reports Third Quarter 2022 Financial Results – Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH – – First demonstration of durable clinical response
Kura Oncology Reports Third Quarter 2022 Abstract reporting updated data from KOMET-001 accepted for oral presentation at ASH First demonstration of durable clinical response with tipifarnib plus alpelisib in HNSCC AIM-HN trial of tipifarnib in HRAS mutant HNSCC closed to furt
Read more →KURAKura Oncology Announces Four Abstracts Accepted for Presentation at ASH Annual Meeting
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts highlighting ziftomenib, the Comp
Read more →KURAKura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million $25 million equity investment from Bristol Myers Squibb at $18.25 per share Term loan
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to $25 million equity investment from Bristol Myers Squibb at $18.25 per share Term loan facility from Hercules Capital provides up to $125 million Proceeds extend K
Read more →KURAUpdate on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia Harry P. Erba 1 , Amir Fathi 2 , Ghayas Issa 3 , Jessica Al
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia Harry P. Erba1, Amir Fathi2, Ghayas Issa3, Jessica Altman4, Pau Montesinos5, Mrinal Patnaik6, James Foran7, Stephane
Read more →KURAKura Oncology to Report Third Quarter 2022 Financial Results
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2022 financial resu
Read more →KURAKura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma
– First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC – – Preclinical data support potential to address ~45% of HNSCC tumors that harbor HRAS overexpression and/or PIK3CA mutation – – Enrollment in the PIK3C
Read more →KURA▲ +8.7%on this news
Kura Oncology to Participate in H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief E
Read more →KURAKura Oncology Reports Second Quarter 2022 Financial Results – Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomen
Kura Oncology Reports Second Quarter 2022 Recommended Phase 2 dose for ziftomenib identified, pending FDA review Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML Preliminary activity observed in KURRENT-HN trial of tipifa
Read more →KURAKura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare V
Read more →KURAKura Oncology to Report Second Quarter 2022 Financial Results
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial res
Read more →KURAKura Oncology Reports First Quarter 2022 Financial Results – Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter 
Kura Oncology Reports First Quarter 2022 Enrollment completed in Phase 1b expansion cohorts for ziftomenib; topline data expected in third quarter, full data presentation in fourth quarter Enrollment in PIK3CA-dependent cohort in KURRENT-HN trial of tipifarnib plus alpelisib co
Read more →KURAKura Oncology to Report First Quarter 2022 Financial Results
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2022 financial res
Read more →KURAKura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer
– Late-breaking presentation at AACR demonstrates potential to significantly delay onset of drug resistance to EGFR-targeted therapies through combination with a farnesyl transferase inhibitor – – Company to initiate clinical trial of tipifarnib in combination with osimertinib i
Read more →KURAKura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Meeting
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that four abstracts have been accepted for presentat
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results – Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML – – Multiple milestones and data rea
Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results Patient enrollment continues in KOMET-001 Phase 1b study of ziftomenib (KO-539) in AML Multiple milestones and data readouts from KOMET-001 expected in 2022 First patients dosed in Phase 1/2 study of tip
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2021
Read more →KURAKura Oncology to Participate in SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the 11th Annual SVB Leerink Glob
Read more →KURAKura Oncology Expands Leadership Team with Key Promotions
SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the expansion of its leadership team with three promo
Read more →KURA▼ -7.5%on this news
Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia
– FDA lifts partial clinical hold following agreement on mitigation strategy for differentiation syndrome – – KOMET-001 study to resume screening and enrollment of new patients – – Encouraging safety, tolerability and clinical activity observed among patients on study – SAN DI
Read more →KURAKura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
– Preclinical data suggest HRAS and PI3Kα are co-dependent oncogenes in HNSCC – – Combination has potential to address up to 50% of patients with HNSCC – – Initial cohort comprised of patients with PIK3CA-dependent HNSCC – SAN DIEGO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Kura Onc
Read more →KURAKura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma
– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma – – Results presented at ASH underscore potential of farnesyl transferase inhibition to drive clinical benefit in cancer patients with
Read more →KURAKura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhibitor KO-539 in Combination with Venetoclax
SAN DIEGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the presentation of new preclinical data for KO-539,
Read more →KURA▼ -15.5%on this news
Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has
Read more →KURAKura Oncology Reports Third Quarter 2021 Financial Results - Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML - - ASH presentation to highlight
Kura Oncology Reports Third Quarter 2021 - Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML - - ASH presentation to highlight molecular mechanisms of activity for KO-539 and potential for synergistic ac
Read more →KURAKura Oncology to Participate in Credit Suisse Healthcare Conference
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30th Annual He
Read more →KURAKura Oncology to Report Third Quarter 2021 Financial Results
SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial resu
Read more →KURAKura Oncology Appoints Teresa Bair as Chief Legal Officer
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer
Read more →KURAKura Oncology Reports Second Quarter 2021 Financial Results - First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 - - Clinical collaboration with Novartis to evaluate tipifarnib in combination
Kura Oncology Reports Second Quarter 2021 - First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 - - Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3K inhibitor alpelisib in HNSCC - - KO-2806 nominated as lead de
Read more →KURAKura Oncology Appoints Helen Collins, M.D. to Board of Directors
Kura Oncology Appoints Helen Collins, M.D. to Board of Directors SAN DIEGO, July 29, 2021 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the ap
Read more →KURAKura Oncology to Report Second Quarter 2021 Financial Results
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial res
Read more →KURAKura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma
– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors – – HNSCC accounts for more than 500,000 new cancer cases each year worldwide, and up to 50% are estimated to be dependent on HRAS and/or PIK3CA
Read more →KURAKura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539
– Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort – – Each cohort to be genetically enriched with NPM1-mutant an
Read more →KURAKura Oncology Appoints Carol Schafer to Board of Directors
Kura Oncology Appoints Carol Schafer to June 4, 2021 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Caro
Read more →KURAKura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Cowen 2nd Annual Virtual Onco
Read more →KURAKura Oncology Reports First Quarter 2021 Financial Results - Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window - - KOMET-001 trial a
Kura Oncology Reports First Quarter 2021 - Menin inhibitor KO-539 continues to demonstrate compelling clinical activity, favorable safety/tolerability and a wide therapeutic window - - KOMET-001 trial amended to include Phase 1b expansion cohorts enriched with NPM1-mutant and K
Read more →KURAKura Oncology to Report First Quarter 2021 Financial Results
SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2021 financial res
Read more →KURAKura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS compared with median PFS of 3.6 months on last prior therapy (p=0.0012) – – Safety p
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results - Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NP
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results - Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations - - KO-539 continues to demonstrate a wide th
Read more →KURAKura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been g
Read more →KURAKura Oncology to Participate in Four Upcoming Investor Conferences
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Ex
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2020
Read more →KURAKura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the H.C. Wainwright BioConnect 2
Read more →KURAKura Oncology to Present at J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 39th Annual J.P. Morgan Heal
Read more →KURAKura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten
Read more →KURAKura Oncology to Participate in the JMP Securities Hematology Summit
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Su
Read more →KURAKura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,1
Read more →KURAKura Oncology Announces Commencement of Public Offering of Common Stock
Kura Oncology Announces Commencement of Public Offering of Common Stock SAN DIEGO, December 7, 2020 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announ
Read more →KURAKura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a SETD2/RUNX1 mutation – – Continuous daily dosing well tolerated and with manageable saf
Read more →KURAKura Oncology to Host Virtual Investor Event on December 5, 2020
SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event to p
Read more →KURAKura Oncology Reports Third Quarter 2020 Financial Results - Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH - - Encouraging safety, tolerability and activity wi
Kura Oncology Reports Third Quarter 2020 - Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH - - Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract - - Preclinical data support expansio
Read more →KURAAbstract accepted for oral presentation at the 62nd American Society of Hematology Annual Meeting Preliminary data on a Phase 1/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed
Abstract accepted for oral presentation at the 62nd American Society of Hematology Annual Meeting Preliminary data on a Phase 1/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia Eunice S. Wang1, Jess
Read more →KURAKura Oncology to Report Third Quarter 2020 Financial Results
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results befo
Read more →KURAKura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract reporting preliminary data from KOMET-001, a
Read more →KURAKura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer
SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Stephen Dale, M.D., as Chief Medical Offic
Read more →KURAKura Oncology Reports Second Quarter 2020 Financial Results - Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH - - Continued progress in registration-directed trial of tipifarnib in HRA
Kura Oncology Reports Second Quarter 2020 - Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH - - Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC - - Opportunity to expand to HRAS and PI3K dependent tumors
Read more →KURAKura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthc
Read more →KURAKura Oncology to Report Second Quarter 2020 Financial Results
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results aft
Read more →KURAKura Oncology to Participate in JMP Securities Hematology & Oncology Forum
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology &
Read more →KURAKura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma - Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/
Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma - Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC - - Outcomes with approved th
Read more →KURAKura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program
SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate t
Read more →KURAKura Oncology to Present at BofA Securities Virtual Health Care Conference 2020
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the BofA Securities Virtual Healt
Read more →KURAKura Oncology Announces Pricing of $125 Million Public Offering of Common Stock
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,10
Read more →KURAKura Oncology Reports First Quarter 2020 Financial Results - Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML - - Three abstracts accepted for pres
Kura Oncology Reports First Quarter 2020 - Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML - - Three abstracts accepted for presentation at ASCO, including mature data from Phase 2 study of tipifarnib in
Read more →KURAKura Oncology to Report First Quarter 2020 Financial Results
SAN DIEGO, April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results aft
Read more →KURAKura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas - Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients - - Company p
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas - Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients - - Company plans to initiate a registration-directed trial of tipifarn
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results - Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quar
Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results - Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 - - Company preparing to initiate a registrati
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2019 financi
Read more →KURAKura Oncology Announces Transition of Chief Medical Officer
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran Dr. Bridget Martell named acting Chief Medical Officer – – Dr. Gualberto to se
Read more →KURAForward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans
Developing Precision Medicines for the Treatment of Cancer J.P. Morgan Healthcare Conference January 13-16, 2020 Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding o
Read more →KURAKura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
SAN DIEGO, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kirsten Flowers as Chief Commercial Office
Read more →KURAKura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial Fast Track designation highlights potential for tipifarnib to address unmet need for pat
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC Registration-directed AIM-HN
Read more →KURAKura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma - Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma - Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma - - Enhanced activity (40% CR rate, 70% ORR)
Read more →KURAKura Oncology to Participate in Piper Jaffray Healthcare Conference
SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Ex
Read more →KURAKura Oncology to Present at Stifel Healthcare Conference
SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Ex
Read more →KURAKura Oncology Announces Upcoming Presentation at ASH Annual Meeting
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s lead drug candidate
Read more →KURAKura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update - Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed t
Kura Oncology Reports Third Quarter 2019 Financial Results and Provides Corporate Update - Updated data from Phase 2 trial of tipifarnib in HRAS mutant HNSCC support enrichment strategy in ongoing registration-directed trial - - Data from Phase 2 trial of tipifarnib in AITL acc
Read more →KURAKura Oncology Appoints James Basta as Chief Legal Officer
SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of James Basta as Chief Legal Officer and Cor
Read more →KURAKura Oncology to Report Third Quarter 2019 Financial Results
SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results afte
Read more →KURAKura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer - 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency 2
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer - 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency 20% - - Median progression-free survival of 6.1 months vs.
Read more →KURAKura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29th – – Previously announced poster presentation rescheduled to take place following oral presentation – – Data embarg
Read more →KURAKura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s Phase 2 clinical tr
Read more →KURAKura Oncology Expands Board of Directors with Appointment of Diane Parks Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness
Kura Oncology Expands Board of Directors with Appointment of Diane Parks Accomplished executive adds extensive experience in launching novel therapies as Company sets sights on commercial readiness SAN DIEGO, October 15, 2019 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
Read more →KURAKura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid Leukemia
– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmac
Read more →KURAKura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma Confirmed objective responses achieved in five of 13 evaluable patients Primary endpoint met prior to completion of enrollm
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial Carcinoma Confirmed objective responses achieved in five of 13 evaluable patients Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survi
Read more →KURAKura Oncology Announces Appointment of Kathleen Ford As Chief Operating Officer Appointment enhances leadership team with focus on strategic planning and operational execution
Kura Oncology Announces Appointment of Kathleen Ford As Chief Operating Officer Appointment enhances leadership team with focus on strategic planning and operational execution SAN DIEGO, August 12, 2019 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical com
Read more →KURAKura Oncology to Present at Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Ex
Read more →KURAKura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing - - Positive Phase 2 trial of tipifarnib in AITL and CXCL
Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update - Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing - - Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration -
Read more →KURAKura Oncology to Report Second Quarter 2019 Financial Results
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2019 financial results aft
Read more →KURAKura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Des
Read more →KURAKura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
SAN DIEGO, July 11, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued
Read more →KURAKura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
SAN DIEGO, June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its co
Read more →KURAKura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts PTCL patients with tumors char
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experie
Read more →KURAKura Oncology to Present at Bank of America Merrill Lynch Health Care Conference
SAN DIEGO, May 08, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is sche
Read more →KURAKura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones - Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track - - Data from ongoing Phase 2 trial of tip
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones - Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track - - Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentati
Read more →KURAKura Oncology to Report First Quarter 2019 Financial Results
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2019 financial results after the close of
Read more →KURAKura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications
– Tipifarnib is a farnesyl transferase inhibitor that downregulates CXCL12 – – Gene expression of the exclusively farnesylated RHOE and PRICKLE2 proteins associated with CXCL12 expression – – Pre-treatment tumor CXCL12 expression identified as a potential biomarker of clinical
Read more →KURAKura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539
– KO-539 is a potent, selective small molecule inhibitor of the menin-MLL interaction – – Robust anti-tumor activity observed in mixed lineage leukemias rearranged and oncogenic driver mutations in genes such as NPM1 – – Phase 1 clinical trial in relapsed or refractory AML expe
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results - Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway - - Data from three ongoing Phase 2 trials of tipifarnib anticipated thi
Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results - Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway - - Data from three ongoing Phase 2 trials of tipifarnib anticipated this year - - Third drug candidate menin-MLL inhibitor KO-53
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2018 financial results afte
Read more →KURAKura Oncology to Present at SVB Leerink Global Healthcare Conference
SAN DIEGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is sch
Read more →KURAKura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer – – Analysis of a previously conducted, randomized Phase 3 trial reveals patients with lymph node or liver metastases and those with no abdominal pain appea
Read more →KURAKura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma - Two CRs, four PRs (46% ORR) observed in advanced
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma - Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL - - A
Read more →KURAKura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
– AITL patent expands protection for tipifarnib, provides exclusivity in U.S. to 2037 – – Prospective data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upcoming at ASH 2018 – SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA)
Read more →KURAKura Oncology Adds Commercial Veteran Mary Szela to Board of Directors - Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial
Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors - Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial - SAN DIEGO, November 8, 2018 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage bioph
Read more →KURAKura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical compan
Read more →KURAKura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update - Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway - - Encouraging preliminary clinical activity observe
Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update - Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway - - Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort - - Preliminary data from AIT
Read more →KURAKura Oncology Announces Upcoming Presentations at ASH Annual Meeting
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company’s lead product candidate, tipifarn
Read more →KURAKura Oncology to Report Third Quarter 2018 Financial Results
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2018 financial results after the close of
Read more →KURAKura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC - Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including si
Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC - Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization
Read more →KURAKura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
SAN DIEGO, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., Kura’s President and Chief Executive Officer
Read more →KURAKura Oncology to Present at H.C. Wainwright Global Investment Conference
SAN DIEGO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the H.C. Wainwright 20th Annual Global Investment Confe
Read more →KURAKura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the 2018 Wedbush PacGrow Healthcare Conference. Troy Wi
Read more →KURAKura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at
Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update - Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 - - Startup activities initiated for upcoming r
Read more →KURAKura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer - Investment banking veteran brings two decades of experience in finance and corporate strategy in the biopharma industry
Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer - Investment banking veteran brings two decades of experience in finance and corporate strategy in the biopharma industry - SAN DIEGO, July 31, 2018 - Kura Oncology, Inc. (Nasdaq: KU
Read more →KURAKura Oncology to Report Second Quarter 2018 Financial Results
SAN DIEGO, July 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report second quarter 2018 financial results after the close of
Read more →KURAKura Oncology Announces Pricing of $67 Million Public Offering of Common Stock
SAN DIEGO, June 28, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 4,000,000 shares of its com
Read more →KURAKura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial - John Farnam appointed to newly created position of Chief Operating Officer - -
Kura Oncology Appoints Chief Operating Officer, Expands Clinical Development Team as Company Prepares for First Registration-Directed Trial - John Farnam appointed to newly created position of Chief Operating Officer - - Bridget Martell, M.D., and Blake Tomkinson, Ph.D., join a
Read more →KURAKura Oncology to Present at JMP Securities Life Sciences Conference
SAN DIEGO, June 14, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., Kura’s President and Chief Executive Officer,
Read more →KURAKura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update - Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in s
Kura Oncology Reports First Quarter 2018 Financial Results and Provides Corporate Update - Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) on track to initiate in second half of 2018 - - Data from multiple Phase 2 trials o
Read more →KURAKura Oncology to Present at Deutsche Bank 43rd Annual Health Care Conference
SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Deutsche Bank 43rd Annual Health Care Conference. Tro
Read more →KURAKura Oncology Announces New Patent for Tipifarnib in Hematologic Malignancies
– Newly issued patent expands protection for tipifarnib in U.S., provides exclusivity in certain CXCL12-expressing cancers to 2037 – – Second U.S. patent for tipifarnib reinforces potential for broader strategy to provide commercial exclusivity based upon biomarker-guided develo
Read more →KURAKura Oncology to Report First Quarter 2018 Financial Results
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2018 financial results after the close of U.
Read more →KURAKura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that three abstracts relating to the company’s lead product candidate, tipif
Read more →KURAKura Oncology to Present at Oppenheimer 28th Annual Healthcare Conference
SAN DIEGO, March 16, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Oppenheimer 28th Annual Healthcare Conference. Troy
Read more →KURAKura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results - Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 followin
Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results - Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA - - Single-ar
Read more →KURAKura Oncology to Present at Cowen and Company 38th Annual Health Care Conference
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Cowen and Company 38th Annual Health Care Conferenc
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2017 financial results afte
Read more →KURAKura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – – Initiation of registrational trial in HRAS mutant HNSCC anticipated this year – SAN DIEG
Read more →KURAKura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation in the Leerink Partners 7th Annual Global Healthcare Confer
Read more →KURAKura Oncology Added to Nasdaq Biotechnology Index
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nas
Read more →KURAKura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase inhibitors Findings support development of tipifarnib in certain
Read more →KURAKura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with RAS wild-type achieved stable disease or better – – Prelimi
Read more →KURAKura Oncology to Host Investor Day on November 16, 2017
SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will host an Investor Day on Thursday, November 16, 2017, from 8:30 a
Read more →KURAKura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update Management to host webcast and conference call today at 4:30 p.m.
Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update Management to host webcast and conference call today at 4:30 p.m. ET SAN DIEGO, November 7, 2017 - Kura Oncology, Inc., (Nasdaq: KURA) a clinical-stage biopharmaceutical company focused on
Read more →KURAKura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that four abstracts relating to the Company’s lead product candidate, tipifar
Read more →KURAKura Oncology to Report Third Quarter 2017 Financial Results
SAN DIEGO, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2017 financial results after the close of U
Read more →KURAKura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patients Menin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO, Oct. 28, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical comp
Read more →KURAKura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC Update
Confirmed partial responses observed in four out of six patients with HRAS mutant HNSCC Tipifarnib demonstrates rapid and durable responses, with partial responses observed beyond one year Registration-enabling study of tipifarnib in HRAS mutant HNSCC planned for 2018 SAN DIEG
Read more →KURAKura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference
SAN DIEGO, Oct. 16, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced presentations at the AACR-NCI-EORTC International Conference on Molecular Tar
Read more →KURAKura Oncology Announces Positive Phase 2 Study for Tipifarnib in HRAS Mutant Head and Neck Cancer
Four of the first six HRAS mutant HNSCC patients enrolled on study achieve confirmed RECIST partial responses Durable responses greater than one year observed SAN DIEGO, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical stage biopharmaceutical com
Read more →KURAForward Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, pre-clinical and clinical development activities, plan
Corporate Presentation September 2017 Exhibit 99.1 Forward Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, pre-clinical and clinical development activities, plans and pr
Read more →KURAKura Oncology to Participate in Citi’s 12th Annual Biotech Conference
SAN DIEGO, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will pa
Read more →KURAKura Oncology Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 7,700,000 shares of its com
Read more →KURAKura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study Tipifarnib demonstrates high level of clinical activity and durable partial responses in ongoing Phase 2 trial i
Kura Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Tipifarnib Phase 2 Study Tipifarnib demonstrates high level of clinical activity and durable partial responses in ongoing Phase 2 trial in HRAS mutant squamous cell head and neck cancers Managem
Read more →KURAKura Oncology to Report Second Quarter 2017 Financial Results
LA JOLLA, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report second quarter 2017 financial results after the cl
Read more →KURAKura Oncology Announces Issuance of U.S. Patent for Lead Product Candidate Tipifarnib in Head and Neck Cancer
SAN DIEGO, July 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the United States Patent and Trademark Office has issued a patent protec
Read more →KURAKura Oncology Establishes Collaboration with Foundation Medicine to Support Tipifarnib Development in HRAS Mutant Head and Neck Cancer
SAN DIEGO, July 13, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced it has entered into a collaboration agreement with Foundation Medicine, Inc.
Read more →KURAKura Oncology Added to Russell 3000 Index
LA JOLLA, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has been added to the broad U.S. market Russell 3000® Index as
Read more →KURAKura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
LA JOLLA, Calif., June 14, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that clinical and preclinical data for tipifarnib in the treatment of
Read more →KURAKura Oncology Announces Data Presentations for Tipifarnib at the International Conference on Malignant Lymphoma and the European Hematology Association Annual Meeting
LA JOLLA, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that preliminary data from the ongoing Phase 2 clinical trial evaluati
Read more →KURAKura Oncology Reports First Quarter 2017 Operational and Financial Results Management to host webcast and conference call today at 4:30 p.m.
Kura Oncology Reports First Quarter 2017 Operational and Financial Results Management to host webcast and conference call today at 4:30 p.m. EDT LA JOLLA, Calif., May 15, 2017 - Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company focused on the develop
Read more →KURAKura Oncology to Report First Quarter 2017 Financial Results
LA JOLLA, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report first quarter 2017 financial results after the clos
Read more →KURAKura Oncology Granted U.S. Patent for Clinical-Stage ERK Inhibitor, KO-947
LA JOLLA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced issuance of a U.S. patent for KO-947, its drug candidate targeting ex
Read more →KURAKura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947
LA JOLLA, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the first patient has been dosed in its Phase 1 clinical trial o
Read more →KURAKura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 and KO-539
LA JOLLA, Calif., April 05, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the presentation of preclinical data for KO-947, its development cand
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results Management to host webcast and conference call today at 4:30 p.m.
Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results Management to host webcast and conference call today at 4:30 p.m. EDT LA JOLLA, Calif., March 14, 2017 - Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company focus
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2016 Financial Results
LA JOLLA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report fourth quarter and full year 2016 financial resul
Read more →KURAKura Oncology Reports Updated Clinical Activity Data in Ongoing Phase 2 Trial for Tipifarnib
LA JOLLA, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced updated results from the ongoing, Phase 2 trial of tipifarnib, a sele
Read more →KURAKura Oncology Announces Presentation of Preliminary Clinical Data for Tipifarnib in HRAS Mutant Squamous Cell Carcinomas of the Head and Neck at TAT 2017
LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product candidate, tipifarnib, at the 15th International Congress on Targeted Anticancer Therapies
Read more →KURACompany Overview We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Advances in cancer genomics are leading to a new era in oncology i
We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Advances in cancer genomics are leading to a new era in oncology in which a patient s cancer may be extensively characterized for mutations a
Read more →KURAKura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 2 clinical trial of tipifarnib in patients with chronic myelomonocytic leukemia (C
Read more →KURAKura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program
LA JOLLA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 c
Read more →KURAKura Oncology Appoints Steven Stein, M.D. to Board of Directors
Kura Oncology Appoints Steven Stein, M.D. to Board of Directors LA JOLLA, Calif., January 3, 2017 - Kura Oncology, Inc. (Nasdaq: KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its board of directors. Dr. Stein curr
Read more →KURAKura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
LA JOLLA, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification and characterization of KO-947, its development candidate targeting ERK1/2 kinases.
Read more →KURAKura Oncology to Present Preclinical Data on Pipeline Programs at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will be presenting two posters at the EORTC-NCI-AACR Symposium on Molecular Targets and
Read more →KURAKura Oncology Reports Third Quarter 2016 Financial Results Management to host webcast and conference call today at 1:30 p.m. PST/4:30 p.m.
Kura Oncology Reports Third Quarter 2016 Financial Results Management to host webcast and conference call today at 1:30 p.m. PST/4:30 p.m. EST LA JOLLA, Calif., November 7, 2016 - Kura Oncology, Inc., (Nasdaq: KURA) a clinical stage biopharmaceutical company committed to realiz
Read more →KURAKura Oncology Presents Update on Pipeline Programs Targeting RAS-ERK Pathway at European Scientific Oncology Conference
LA JOLLA, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today presented preclinical findings and data from the company’s ongoing Phase 2 trial in HRAS mutant solid tumors at the 9th European Scientific Onc
Read more →KURAKura Oncology to Report Third Quarter 2016 Financial Results
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report third quarter 2016 financial res
Read more →KURAKura Oncology to Participate in the 9th European Scientific Oncology Conference
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European Scientific Oncology Conference. Antonio Gualberto, M.D., Ph.D., Chief Medical Officer, will par
Read more →KURAKura Oncology to Participate in the 2016 Aegis Growth Conference
LA JOLLA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled
Read more →KURAKura Oncology to Participate in the 5th Annual Gateway Conference
LA JOLLA, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to p
Read more →KURAKura Oncology Reports Second Quarter 2016 Financial Results Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host w
Kura Oncology Reports Second Quarter 2016 Financial Results Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at 1:15 p.m. PDT/4:15 p.m
Read more →KURAKura Oncology to Report Second Quarter 2016 Financial Results
LA JOLLA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial results after the close of U.S. financial markets on August 10, 2016. Management will ho
Read more →KURAForward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, pre-clinical and clinical development activities, plan
Troy Wilson, Ph.D., J.D. President and CEO June 16, 2016 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, pre-clinical and clinical development activ
Read more →KURAKura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
LA JOLLA, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2 clinical trial of tipifarnib in patients with lower risk myelodysplastic syndromes (MDS
Read more →KURAKura Oncology to Participate in the 2016 JMP Life Sciences Conference
LA JOLLA, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will par
Read more →KURAKura Oncology to Participate in the Jefferies 2016 Healthcare Conference
LA JOLLA, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the Jefferies 2016 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is sc
Read more →KURAKura Oncology Reports First Quarter 2016 Financial Results
Kura Oncology Reports First Quarter 2016 Financial Results LA JOLLA, Calif., May 11, 2016 - Kura Oncology, Inc., (NASDAQ: KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2016. "Kura has made important prog
Read more →KURAKura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results Management to host webcast and conference call today at 4:30 p.m.
Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results Management to host webcast and conference call today at 4:30 p.m. EDT LA JOLLA, Calif., March 17, 2016 - Kura Oncology, Inc., (NASDAQ: KURA) a clinical stage biopharmaceutical company, tod
Read more →KURAKura Oncology to Report Fourth Quarter and Full Year 2015 Financial Results
LA JOLLA, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that it will report fourth quarter and full year 2015 financial results after the close of U.S. financial markets on March 17, 2016.
Read more →KURAKura Oncology to Participate in the Leerink Global Healthcare Conference
LA JOLLA, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at 2:15 p.m. ET (11:15 a.m.
Read more →KURAKura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting
LA JOLLA, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from a Phase 3 trial of tipifarnib, the company's lead product candidate, will be presented at the 57th American Society
Read more →KURAKura Oncology to Present at the Oppenheimer 2015 Healthcare Conference
LA JOLLA, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 10:55 a.m. EST (7:55
Read more →KURAKura Oncology Announces First Patient Dosed in an Investigator-Sponsored Phase 2 Trial of Tipifarnib in Patients With HRAS Mutant Urothelial Cancer
LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), today announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, an inhibitor of protein farnesylation, in cancer patient
Read more →KURAKura Oncology to Present at Upcoming Investor Conference
LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 11:30 a.m. EST (8:30
Read more →KURAKura Oncology to Present at the Jefferies 2015 Global Healthcare Conference
LA JOLLA, Calif., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, will present an overview of the company at 2:40 p.m. GMT (6:40
Read more →KURAKura Oncology Announces Launch of Public Offering of Common Stock
LA JOLLA, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced that it has commenced an underwritten
Read more →KURADESCRIPTION OF OUR BUSINESS Overview We are a clinical stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. We focus on the development
DESCRIPTION OF OUR BUSINESS We are a clinical stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. We focus on the development of small molecule product candidates that target cell signaling pa
Read more →KURAKura Oncology Appoints Thomas Malley to Board of Directors
Kura Oncology Appoints Thomas Malley to Board of Directors LA JOLLA, Calif., October 14, 2015 Kura Oncology, Inc. (OTCQB: KURO), a clinical stage biopharmaceutical company, today announced the appointment of Thomas Malley to its board of directors. Tom has extensive knowledge
Read more →KURAKura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
LA JOLLA, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced it has initiated a Phase 2 clinical t
Read more →KURAKura Oncology Cleared for Quotation on the OTCQB
LA JOLLA, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (OTCQB:KURO), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced today that its common stock has been approv
Read more →KURAForward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research and clinical development plans and projected timelines
Troy Wilson, Ph.D., J.D. President and Chief Executive Officer August 2015 Exhibit 99.1 Forward-looking statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research and clinical development p
Read more →KURAKura Oncology to Present at the 2015 Wedbush PacGrow Healthcare Conference
LA JOLLA, Calif., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced its participation in the 2015 Wedbush PacGrow Health
Read more →KURAKura Oncology's Menin-MLL Inhibitor Program Shows Promise in Study Published in Cancer Cell; Program Targeting Acute Leukemias Licensed From University of Michigan
LA JOLLA, Calif., March 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. ("Kura Oncology" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, announced a study published by
Read more →KURAKura Oncology, Inc. Financial Statements Contents Report of Independent Registered Public Accounting Firm F-1 Balance Sheet F-2 Statement of Operations and Comprehensive Loss F-3 Statement of Stockholders Deficit F-4 Sta
Financial Statements Report of Independent Registered Public Accounting Firm F-1 Balance Sheet F-2 Statement of Operations and Comprehensive Loss F-3 Statement of Stockholders Deficit F-4 Statement of Cash Flows F-5 Notes to Financial Statements F-6 Report of
Read more →KURAKura Oncology Announces License Agreement With Janssen Pharmaceutica for Development and Commercialization of Tipifarnib; Closes $60 Million Private Placement and Completes Reverse Merger
LA JOLLA, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. ("Kura Oncology" or the "Company"), a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers, today announced several milesto
Read more →Competitive Position
How KURA ranks across every disease it competes inCompetitive Position is a premium feature
See how KURA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial